Vi-DT typhoid conjugate vaccine met primary endpoints in phase III study Vi-DT typhoid conjugate vaccine, developed jointly by the International Vaccine Institute (IVI) and SK bioscience, has met the primary endpoints in a phase III study in Nepal. The primary endpoints were based on immune non-inferiority with the WHO-prequalified typhoid conjugate vaccine, Typbar-TCV®, in terms of serconversion rate, which confirms the new candidate TCV induces an immune response that is not inferior to Typbar-TCV®. Three different production lots of vaccine were administered in the clinical trial, and the analysis also shows that these different batches were similar in immunogenicity. Lot-to-lot consistency in manufacturing is an important requirement to ensure the quality of Vi-DT.